Saint Cyr Au Mont D Or

Researchers are evaluating the effects of transcranial direct current stimulation (tDCS) on cannabis use disorder in people with schizophrenia. Cannabis use disorder often occurs alongside schizophrenia and is linked to increased symptoms and lower treatment adherence. Current treatments have limited success, so this study aims to test if 10 sessions of tDCS targeting specific brain areas can reduce cannabis use, craving, addiction severity, schizophrenia symptoms, and improve overall functioning in 110 participants. The study involves two groups: one receiving active tDCS and the other receiving sham (inactive) stimulation. The active treatment uses a Neurocan DC-Stimulator Plus with electrodes placed on the right dorsolateral prefrontal cortex and medial prefrontal cortex. Stimulation is set at 2 mA for 20 minutes, twice a day with at least 3 hours between sessions, over 5 consecutive weekdays. The sham group follows the same schedule but receives a placebo-like stimulation that mimics the sensations without active effects. Participants will be monitored for changes in cannabis use over 6 months along with assessments of craving, addiction severity, schizophrenia symptoms, global functioning, cognitive functions, and brain connectivity. The study includes clinical evaluations and safety monitoring to understand the impact of tDCS on this population and the potential changes in brain function associated with treatment.